
EquitySector - HealthcareVery High Risk
Direct
NAV (25-Nov-25)
Returns (Since Inception)
Fund Size
₹847 Cr
Expense Ratio
1.03%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+1.78%
+3.30% (Cat Avg.)
3 Years
+22.42%
+22.18% (Cat Avg.)
5 Years
+17.08%
+17.04% (Cat Avg.)
Since Inception
+21.20%
— (Cat Avg.)
| Equity | ₹819.69 Cr | 96.74% |
| Others | ₹27.59 Cr | 3.26% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹98.24 Cr | 11.60% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹65.24 Cr | 7.70% |
| Cipla Ltd | Equity | ₹56.61 Cr | 6.68% |
| Fortis Healthcare Ltd | Equity | ₹38.63 Cr | 4.56% |
| Lupin Ltd | Equity | ₹38.53 Cr | 4.55% |
| Abbott India Ltd | Equity | ₹37.5 Cr | 4.43% |
| Torrent Pharmaceuticals Ltd | Equity | ₹36.47 Cr | 4.30% |
| Ajanta Pharma Ltd | Equity | ₹31.88 Cr | 3.76% |
| Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹28.38 Cr | 3.35% |
| Ipca Laboratories Ltd | Equity | ₹27.99 Cr | 3.30% |
| Aurobindo Pharma Ltd | Equity | ₹25.2 Cr | 2.97% |
| Mankind Pharma Ltd | Equity | ₹23.98 Cr | 2.83% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹23.71 Cr | 2.80% |
| Emcure Pharmaceuticals Ltd | Equity | ₹23.44 Cr | 2.77% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹20.87 Cr | 2.46% |
| Thyrocare Technologies Ltd | Equity | ₹19.31 Cr | 2.28% |
| Alkem Laboratories Ltd | Equity | ₹19.29 Cr | 2.28% |
| Divi's Laboratories Ltd | Equity | ₹17.52 Cr | 2.07% |
| Sai Life Sciences Ltd | Equity | ₹16.99 Cr | 2.00% |
| Alembic Pharmaceuticals Ltd | Equity | ₹16.63 Cr | 1.96% |
| Shilpa Medicare Ltd | Equity | ₹15.07 Cr | 1.78% |
| Medi Assist Healthcare Services Ltd | Equity | ₹14.89 Cr | 1.76% |
| Metropolis Healthcare Ltd | Equity | ₹13.23 Cr | 1.56% |
| Anthem Biosciences Ltd | Equity | ₹13.1 Cr | 1.55% |
| Dr Reddy's Laboratories Ltd | Equity | ₹11.85 Cr | 1.40% |
| Procter & Gamble Health Ltd | Equity | ₹11.72 Cr | 1.38% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹10.74 Cr | 1.27% |
| Suraksha Diagnostic Ltd | Equity | ₹10.64 Cr | 1.26% |
| Jubilant Pharmova Ltd | Equity | ₹10.45 Cr | 1.23% |
| Biocon Ltd | Equity | ₹10.11 Cr | 1.19% |
| Gland Pharma Ltd | Equity | ₹9.64 Cr | 1.14% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹9.28 Cr | 1.09% |
| Piramal Pharma Ltd | Equity | ₹8.78 Cr | 1.04% |
| Pfizer Ltd | Equity | ₹8.59 Cr | 1.01% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.03 Cr | 0.95% |
| Vinati Organics Ltd | Equity | ₹7.8 Cr | 0.92% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹7.73 Cr | 0.91% |
| Net Receivables / (Payables) | Cash | ₹-0.79 Cr | 0.09% |
Large Cap Stocks
42.07%
Mid Cap Stocks
23.76%
Small Cap Stocks
29.36%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹811.89 Cr | 95.82% |
| Basic Materials | ₹7.8 Cr | 0.92% |
Standard Deviation
This fund
16.06%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
0.94
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since July 2019
ISIN INF209KB1O25 | Expense Ratio 1.03% | Exit Load 1.00% | Fund Size ₹847 Cr | Age 6 years 4 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹4,21,159 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Direct
NAV (25-Nov-25)
Returns (Since Inception)
Fund Size
₹847 Cr
Expense Ratio
1.03%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+1.78%
+3.30% (Cat Avg.)
3 Years
+22.42%
+22.18% (Cat Avg.)
5 Years
+17.08%
+17.04% (Cat Avg.)
Since Inception
+21.20%
— (Cat Avg.)
| Equity | ₹819.69 Cr | 96.74% |
| Others | ₹27.59 Cr | 3.26% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹98.24 Cr | 11.60% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹65.24 Cr | 7.70% |
| Cipla Ltd | Equity | ₹56.61 Cr | 6.68% |
| Fortis Healthcare Ltd | Equity | ₹38.63 Cr | 4.56% |
| Lupin Ltd | Equity | ₹38.53 Cr | 4.55% |
| Abbott India Ltd | Equity | ₹37.5 Cr | 4.43% |
| Torrent Pharmaceuticals Ltd | Equity | ₹36.47 Cr | 4.30% |
| Ajanta Pharma Ltd | Equity | ₹31.88 Cr | 3.76% |
| Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹28.38 Cr | 3.35% |
| Ipca Laboratories Ltd | Equity | ₹27.99 Cr | 3.30% |
| Aurobindo Pharma Ltd | Equity | ₹25.2 Cr | 2.97% |
| Mankind Pharma Ltd | Equity | ₹23.98 Cr | 2.83% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹23.71 Cr | 2.80% |
| Emcure Pharmaceuticals Ltd | Equity | ₹23.44 Cr | 2.77% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹20.87 Cr | 2.46% |
| Thyrocare Technologies Ltd | Equity | ₹19.31 Cr | 2.28% |
| Alkem Laboratories Ltd | Equity | ₹19.29 Cr | 2.28% |
| Divi's Laboratories Ltd | Equity | ₹17.52 Cr | 2.07% |
| Sai Life Sciences Ltd | Equity | ₹16.99 Cr | 2.00% |
| Alembic Pharmaceuticals Ltd | Equity | ₹16.63 Cr | 1.96% |
| Shilpa Medicare Ltd | Equity | ₹15.07 Cr | 1.78% |
| Medi Assist Healthcare Services Ltd | Equity | ₹14.89 Cr | 1.76% |
| Metropolis Healthcare Ltd | Equity | ₹13.23 Cr | 1.56% |
| Anthem Biosciences Ltd | Equity | ₹13.1 Cr | 1.55% |
| Dr Reddy's Laboratories Ltd | Equity | ₹11.85 Cr | 1.40% |
| Procter & Gamble Health Ltd | Equity | ₹11.72 Cr | 1.38% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹10.74 Cr | 1.27% |
| Suraksha Diagnostic Ltd | Equity | ₹10.64 Cr | 1.26% |
| Jubilant Pharmova Ltd | Equity | ₹10.45 Cr | 1.23% |
| Biocon Ltd | Equity | ₹10.11 Cr | 1.19% |
| Gland Pharma Ltd | Equity | ₹9.64 Cr | 1.14% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹9.28 Cr | 1.09% |
| Piramal Pharma Ltd | Equity | ₹8.78 Cr | 1.04% |
| Pfizer Ltd | Equity | ₹8.59 Cr | 1.01% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.03 Cr | 0.95% |
| Vinati Organics Ltd | Equity | ₹7.8 Cr | 0.92% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹7.73 Cr | 0.91% |
| Net Receivables / (Payables) | Cash | ₹-0.79 Cr | 0.09% |
Large Cap Stocks
42.07%
Mid Cap Stocks
23.76%
Small Cap Stocks
29.36%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹811.89 Cr | 95.82% |
| Basic Materials | ₹7.8 Cr | 0.92% |
Standard Deviation
This fund
16.06%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
0.94
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since July 2019
ISIN INF209KB1O25 | Expense Ratio 1.03% | Exit Load 1.00% | Fund Size ₹847 Cr | Age 6 years 4 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹4,21,159 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments